首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Histone deacetylase inhibitor-induced sensitization to TNFalpha/TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression.
【24h】

Histone deacetylase inhibitor-induced sensitization to TNFalpha/TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression.

机译:组蛋白脱乙酰基酶抑制剂对宫颈癌细胞中TNFα/ TRAIL介导的细胞凋亡的敏感性取决于HPV癌基因的表达。

获取原文
获取原文并翻译 | 示例
           

摘要

Histone-deacetylase (HDAC) inhibitors (HDACi) can block proliferation and induce intrinsic apoptosis in human papillomavirus (HPV)-positive cervical carcinoma cells, independently of copy number and integration locus of the viral DNA. Using HPV18-positive HeLa cells as model systems, we provide evidence that HDAC inhibition leads to transcriptional suppression of c-FLIP, which negatively regulates extrinsic apoptosis by preventing the recruitment of caspase-8 to the death-inducing signaling complex. Consequently, HDACi pretreatment renders cervical cancer cells sensitive to TNFalpha and TRAIL-induced apoptosis. Already 5-hr incubation with TNFalpha or TRAIL was sufficient to eradicate more than 40% of pretreated cells, which are normally completely refractory against respective death-ligands alone even under long-term incubation. Ectopic expression of either short or long splicing variant of c-FLIP, c-FLIP(s) and c-FLIP(L), abrogates sensitization. Notably, combined HDACi/death ligand treatment did not result in eradication of HPV-negative cells, despite the fact that both c-FLIP isoforms were also downregulated. However, knocking down HPV18 E6/E7 transcription by siRNA prevents HDACi/death-ligand mediated apoptosis, indicating that continued viral oncogene expression favors sensitization. Here, the viral oncoprotein E7 seems to play a functional role, since only HPV16 E7-immortalized human keratinocytes underwent significant apoptosis on HDACi/TNFalpha treatment, whereas keratinocytes expressing only HPV16 E6 or primary keratinocytes were refractory under the same experimental conditions. Taken together, HDACi can be considered as an alternative therapeutic option in the treatment of premalignant and malignant lesions.
机译:组蛋白脱乙酰基酶(HDAC)抑制剂(HDACi)可以阻断人乳头瘤病毒(HPV)阳性宫颈癌细胞的增殖并诱导内在凋亡,而与病毒DNA的拷贝数和整合位点无关。使用HPV18阳性HeLa细胞作为模型系统,我们提供证据表明HDAC抑制导致c-FLIP的转录抑制,该c-FLIP通过阻止caspase-8募集到诱导死亡的信号复合体中而负调控外在凋亡。因此,HDACi预处理使宫颈癌细胞对TNFalpha和TRAIL诱导的细胞凋亡敏感。已经用TNFalpha或TRAIL进行了5小时的温育足以根除40%以上的预处理细胞,即使在长期温育下,它们通常对单独的死亡配体也是完全难治的。 c-FLIP,c-FLIP和c-FLIP(L)的短或长剪接变体的异位表达消除了致敏作用。值得注意的是,尽管事实上两个c-FLIP亚型也均被下调,但HDACi /死亡配体联合治疗并未导致HPV阴性细胞的清除。但是,通过siRNA抑制HPV18 E6 / E7转录可阻止HDACi /死亡配体介导的凋亡,这表明持续的病毒癌基因表达有利于敏化。在这里,病毒癌蛋白E7似乎起着功能性作用,因为只有HPV16 E7永生化的人角质形成细胞在HDACi / TNFalpha处理后才发生明显的细胞凋亡,而在相同的实验条件下,仅表达HPV16 E6的角质形成细胞或原代角质形成细胞是难治性的。综上所述,HDACi可被视为恶性前病变和恶性病变的替代治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号